Across TCGA pan-cancer cohorts, SNORA37 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SNORA37’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where SNORA37 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SNORA37 is over-expressed in tumor, although a few such as LUAD and READ show the opposite, repressed pattern.

BRCA, LUSC, and LUAD are the cancer types where SNORA37 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SNORA37 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	IV	+0.515	<.001	6	view →
LUSC	All	All	+0.314	.001	5	view →
LUAD	Female	III,IV	−0.431	.038	1	view →
READ	All	II,III,IV	−0.342	.024	1	view →
THCA	All	II,III,IV	−0.285	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SNORA37 RNA expression & survival · all SNORA37 data types